PR+ breast cancer responds well to hormone therapy, underscoring the need for molecular insight and targeted treatment ...

ER+/PR+ breast cancer, common and hormone-responsive, offers a better prognosis and is key in treatment research advancements ...

Parturition is a complex and involved process. Within the protected confines of the mother, the fetus grows rapidly for 37–42 weeks until the right combination of signals, stemming from both ...

Around 10% of all breast cancers are hormone receptor-positive and HER2-positive. Estrogen and progesterone receptors are proteins in cells that attach to the hormones estrogen and progesterone to ...

Cancer cells with estrogen or progesterone hormone receptors can grow in response to those hormones. When tumors are human epidermal growth factor receptor 2-negative (HER2-), they contain few to ...

Ulipristal acetate, a selective progesterone receptor modulator, combined with misoprostol resulted in pregnancy termination among nearly all participants in a small proof-of-concept study.

It would be short-sided, erroneous and dangerous to think ill of mifepristone, which has several important applications,, M.D ...

Estrogen and progesterone combined in OCs act in a synergistic ... androgenic effect by their linkage with the androgenic receptor. On the other hand, progestins counter the beneficial estrogen ...

At low doses it blocks the naturally occurring hormone progesterone from binding to its receptor in the body. This is one of the mechanisms by which it has been used in abortion care, as it blocks ...